Brown SGA - Search Results

1

The development of Jack Jumper ant venom immunotherapy: our 25 years' experience.

Wanandy T, Le TA, Lau WY, Wiese MD, Heddle RJ, Brown SGA. Wanandy T, et al. Among authors: brown sga. Intern Med J. 2023 Sep;53(9):1716-1721. doi: 10.1111/imj.16217. Intern Med J. 2023. PMID: 37743244

2

Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania.

Brown SG, Franks RW, Baldo BA, Heddle RJ. Brown SG, et al. J Allergy Clin Immunol. 2003 Jan;111(1):187-92. doi: 10.1067/mai.2003.48. J Allergy Clin Immunol. 2003. PMID: 12532117

3

Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial.

Brown SG, Wiese MD, Blackman KE, Heddle RJ. Brown SG, et al. Lancet. 2003 Mar 22;361(9362):1001-6. doi: 10.1016/S0140-6736(03)12827-9. Lancet. 2003. PMID: 12660058 Clinical Trial.

4

Prevention of anaphylaxis with ant venom immunotherapy.

Brown SG, Heddle RJ. Brown SG, et al. Curr Opin Allergy Clin Immunol. 2003 Dec;3(6):511-6. doi: 10.1097/00130832-200312000-00014. Curr Opin Allergy Clin Immunol. 2003. PMID: 14612677 Review.

5

Characterisation of major peptides in 'jack jumper' ant venom by mass spectrometry.

Davies NW, Wiese MD, Brown SG. Davies NW, et al. Toxicon. 2004 Feb;43(2):173-83. doi: 10.1016/j.toxicon.2003.11.021. Toxicon. 2004. PMID: 15019477 Free article.

6

Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine.

Wiese MD, Milne RW, Davies NW, Chataway TK, Brown SG, Heddle RJ. Wiese MD, et al. J Pharm Biomed Anal. 2008 Jan 7;46(1):58-65. doi: 10.1016/j.jpba.2007.08.028. Epub 2007 Sep 7. J Pharm Biomed Anal. 2008. PMID: 17933477

7

Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy.

Wiese MD, Davies NW, Chataway TK, Milne RW, Brown SG, Heddle RJ. Wiese MD, et al. J Pharm Biomed Anal. 2011 Jan 25;54(2):303-10. doi: 10.1016/j.jpba.2010.08.024. Epub 2010 Sep 24. J Pharm Biomed Anal. 2011. PMID: 20869831

8

Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial.

Brown SG, Wiese MD, van Eeden P, Stone SF, Chuter CL, Gunner J, Wanandy T, Phillips M, Heddle RJ. Brown SG, et al. J Allergy Clin Immunol. 2012 Jul;130(1):162-8. doi: 10.1016/j.jaci.2012.02.022. Epub 2012 Mar 27. J Allergy Clin Immunol. 2012. PMID: 22460067 Clinical Trial.

9

Pilosulins: a review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula.

Wanandy T, Gueven N, Davies NW, Brown SG, Wiese MD. Wanandy T, et al. Toxicon. 2015 May;98:54-61. doi: 10.1016/j.toxicon.2015.02.013. Epub 2015 Feb 25. Toxicon. 2015. PMID: 25725257 Review.

10

Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach.

Wanandy T, Wilson R, Gell D, Rose HE, Gueven N, Davies NW, Brown SGA, Wiese MD. Wanandy T, et al. Among authors: brown sga. Clin Exp Allergy. 2018 Sep;48(9):1222-1234. doi: 10.1111/cea.13224. Epub 2018 Aug 3. Clin Exp Allergy. 2018. PMID: 29975807

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

124 results

Search Page